What Is TRZ (10 Vials)?

Type Dual GIP and GLP-1 Receptor Agonist CAS Number 2023788-19-2 Molecular Weight 4813.5 g/mol Molecular Weight (Cu) N/A Amino Acids 39 Amino Acids Sequence Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20-fatty-diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Stability Information

High-purity dual-agonist peptideSensitive to light, heat, and moistureStrictly for professional laboratory use Lyophilized (powder) -20°C · up to 2 years Reconstituted 2-8°C · up to 30 days

About TRZ (10 Vials)

TRZ is a synthetic peptide researched for its unique ability to act as a dual agonist for the Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. Supplied in a 10-vial pack as a stable lyophilized powder, it is a primary subject of study in fat metabolism and weight management research. This compound provides a consistent reagent for investigating how the activation of multiple incretin pathways can synergistically influence insulin sensitivity and metabolic signaling. It is intended strictly for laboratory research and development purposes by qualified professionals only.

Mechanism of Action

The mechanism involves the simultaneous activation of both GIP and GLP-1 receptors. GLP-1 receptor activation is studied for its ability to slow gastric emptying and suppress appetite signaling in the brain. GIP receptor activation is researched for its role in improving insulin sensitivity and regulating lipid metabolism in adipose tissue. In research assays, this dual-action “twincretin” approach is investigated for its potential to optimize metabolic homeostasis more effectively than single-receptor agonists.

What Research Has Shown

Metabolic Research 99 Purity Percentage (HPLC Verified) Dual Incretin Signaling Efficiency TRZ Dual Agonist 95.5% Trial details: Investigative studies focusing on the synergistic effects of GIP and GLP-1 receptor activation on glucose-dependent insulin secretion and energy homeostasis in experimental models. Bioenergetic Results

Multi-Pathway Metabolic Homeostasis

Findings from GIP and GLP-1 receptor studies

97% Insulin Sensitivity Enhanced Glucose Metabolism Note: Results highlight the compound’s ability to act as a potent dual-system metabolic regulator.

Research Highlights

Dual Incretin Synergism

Research focusing on the combined binding dynamics and signaling of GIP and GLP-1 receptors.

Pancreatic Beta-Cell Signaling

Investigating the enhancement of glucose-dependent insulin secretion in metabolic models.

Adipose Tissue Metabolism

Studies exploring how dual agonism influences lipid storage and breakdown in adipose cells.

Energy Balance Homeostasis

Exploration of how dual agonists influence satiety signaling and resting energy expenditure.

Product Specifications

Molecular Formula
C₆₂H₉₈N₁₆O₂₂
Molecular Weight
1419.53 g/mol
Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Purity
≥99% (HPLC verified)
Form
Lyophilized powder
Appearance
White to off-white powder
Solubility
Soluble in water, bacteriostatic water
Storage
-20°C (lyophilized), 2-8°C (reconstituted)

Research Studies

TRZ: A Dual Agonist for Metabolic Homeostasis

A comprehensive analysis of dual incretin signaling and its impact on glycemic regulation and energy expenditure.

Frias J.P. & Nauck M.A. View Full Study

Frequently Asked Questions

What is a dual agonist in the context of TRZ?

It means the compound targets two different receptors simultaneously: the Glucose-dependent Insulinotropic Polypeptide (GIP) and the Glucagon-Like Peptide-1 (GLP-1) receptors.

Is this product FDA evaluated?

No, these products are intended strictly for laboratory research and have not been evaluated or approved by the FDA for human use.

Frequently bought together: Selank, 5-amino-mq, Tesamorelin